CEO John Q Doyle sold 16,656 shares of MRSH at $161.71 on 2026-06-02 via pre-arranged 10b5-1 plan; holds 116,811 non-derivative shares post-transaction.
President and CEO John Q Doyle executed a scheduled sale of 16,656 shares at $161.71 under a pre-arranged 10b5-1 trading plan on 2026-06-02, reducing his non-derivative holdings to 116,811 shares from 133,467 shares (-12.5%). The transaction is part of a predetermined plan rather than a discretionary decision, removing timing-based interpretation. The stock has since declined 18.6% from its 52-week high of $193.32 and is currently trading at $157.32, below the transaction price. While this marks a scheduled vest-and-sell action, Doyle retains 33,312 shares through stock options, maintaining meaningful economic exposure to the company. The company remains fundamentally healthy with $7.6B in quarterly revenue, $1.1B in net income, and a P/E of 19.30.